NCT01259531

Study of a α1A Adrenoceptor Selective Antagonist Silodosin to Treat Severe Benign Prostatic Hyperplasia(BPH)

A 12-week, Open Label, Multi-center Study to Investigate the Efficacy and Safety of a α1A Adrenoceptor Selective Antagonist Silodosin on Urinary Disturbance Associated With Benign Prostatic Hyperplasia

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: JW Pharmaceutical · Industry
• Sex: Male
• Age: 50 Years
• Healthy volunteers: Not accepted

Summary

This clinical study is designed to evaluate the efficacy and safety of silodosin in a 12 week treatment of patients with severe urinary disorders associated with benign prostatic hyperplasia (BPH).

Conditions

• Benign Prostatic Hyperplasia

Interventions

Type	Name	Description
DRUG	Silodosin	Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.

Timeline

• Start date: 2010-12-01
• Primary completion: 2011-09-01
• Completion: 2011-09-01
• First posted: 2010-12-14
• Last updated: 2012-03-30

Locations

1 site across 1 country: South Korea